Posted by Michael Wonder on 22 Apr 2021
Allogene Therapeutics announces FDA regenerative medicine advanced therapy designation granted to ALLO-715, an AlloCAR T cell therapy in development for relapsed/refractory multiple myeloma
21 April 2021 - Regenerative medicine advanced therapy designation follows proof of concept data from ALLO-715 UNIVERSAL trial in heavily pretreated, refractory multiple myeloma patients.
Allogene Therapeutics today announced that the U.S. FDA granted regenerative medicine advanced therapy designation to ALLO-715 in relapsed/refractory multiple myeloma.
